相关实验视频

Updated: May 22, 2025

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

通过NSA2-EGFR-P53信号通路增强抗瘤活性的新型坎普托塞辛衍生物9c

Fu Du^1,2, Aotong Zhang^1,2, Xin Qi^1,2

¹Key Laboratory of Marine Drugs, Chinese Ministry of Education, School of Medicine and Pharmacy, Ocean University of China, Qingdao 266003, China.

International journal of molecular sciences

|March 13, 2025

概括

一种新型的坎普托塞辛衍生物,9c通过诱导细胞死亡和抑制瘤生长,显示出强大的抗非小细胞肺癌 (NSCLC) 活性. 这种新化合物克服了耐药性,并增强了其他癌症疗法.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
药物发现药物发现药物发现

背景情况:

非小细胞肺癌 (NSCLC) 提出了重大的治疗挑战.
坎普托塞辛是有效的抗癌药物,但由于毒性和耐药性而面临限制.
现有的治疗方法需要新的方法来改善患者的治疗结果.

研究的目的:

引入和评估一种新型的坎普托塞辛衍生物,指定9c,其抗NSCLC疗效.
阐明9c在抑制NSCLC进展中的作用机制.
评估9c在NSCLC的联合治疗中的潜力.

主要方法:

新型坎普托他衍生物9c.的合成和表征.
在体外研究评估细胞循环停止,亡诱导和基因表达.
在体内异种移植模型评估瘤生长抑制和毒性.
与AMG510对KRAS突变NSCLC的组合研究.

主要成果:

9c与FL118.8相比,显示出更高的抗NSCLC功效.
9c诱导细胞循环停止和细胞亡通过下调抗细胞亡基因 (幸存者,Mcl-1,Bcl-2,XIAP).
9c通过破坏NSA2-EGFR轴的稳定性来促进野生类型的p53表达,从而导致细胞亡.
9c在体内显著抑制NSCLC异种移植生长,没有观察到毒性.
9c在KRAS突变NSCLC模型中显示了与AMG510的治疗协同作用.

结论:

9c代表了一种有前途的新型坎普托他辛衍生物用于NSCLC治疗.
它的机制涉及p53诱导和关键生存途径的下调.
9c表现出良好的安全性和组合治疗的潜力,提供针对NSCLC的创新策略.

关键词:

欧洲农业基金会 (EGFR) 是一个.美国国家安全局NSA2 在P53中,P53是P53 这是一种抗瘤药物.坎普托西因衍生品坎普托西因衍生品

更多相关视频

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen

Published on: May 30, 2012

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

相关概念视频

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...